The research group of KU Leuven in collaboration with the Erasmus University Medical Center, established a research programme exploring the market environment of biologics including biosimilars following loss of exclusivity, called the MABEL Fund. The research activities of the MABEL group aim to capture full market dynamics for originator biologics, biosimilars and second-generation biologics and to investigate the evolution of strategies for market access and uptake of these products. These aspects are explored by various PhD researchers over an extended period of time, allowing the group to investigate the effects of a changing market environment and to evaluate how these changes may affect the long-term sustainability of the off-patent biologics and biosimilars marketplace. PhD projects Evelien Moorkens - A multifaceted view on market access of biosimilars (2015 - 2020) Liese Barbier – A multi-stakeholder view on the regulatory evaluation and market access of biosimilars in Europe (2016 - present) Teresa Barcina – Exploring market dynamics and sustainability of off-patent biologics and biosimilar medicines in Europe (2019 - present)